Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ: EXEL )

35.00 +0.51 (+1.48%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
A Glimpse Into The Expert Outlook On Exelixis Through 21 Analysts
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Exelixis (EXEL) Q4 2024 Earnings Call Transcript
EXEL earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Exelixis Posts 63.7% Profit Surge
Exelixis reported increased revenue and earnings in Q4 2024, driven by strong cabozantinib sales, though competitive pressures and regulatory challenges remain. 
Via The Motley Fool
NASDAQ:EXEL: good value for what you're paying.
EXELIXIS INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:EXEL showcases decent financial health and profitability, coupled with an attractive price. 
Via Chartmill
Investors should take note of NASDAQ:EXEL, a growth stock that remains attractively priced.
Uncover the potential of EXELIXIS INC, a growth stock reasonably priced. NASDAQ:EXEL is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive valuation. 
Via Chartmill
15 Analysts Have This To Say About Exelixis
Via Benzinga
In the world of growth stocks, NASDAQ:EXEL shines as a value proposition.
NASDAQ:EXEL is showing decent growth, but is still valued reasonably. 
Via Chartmill
(EXEL) - Analyzing Exelixis's Short Interest
Via Benzinga
Earnings Scheduled For February 11, 2025
Via Benzinga
2 Stocks to Buy With Less Than $40
Via The Motley Fool
Peering Into Exelixis's Recent Short Interest
Via Benzinga
Abbott To Rally Over 26%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
This Twilio Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
BeiGene Stock Meets 80-Plus RS Rating Benchmark
One key metric to look for in a stock is an 80-plus Relative Strength Rating. BeiGene stock just hit that mark, with a jump to 84 Wednesday. 
Via Investor's Business Daily
BridgeBio Pharma Stock Earns 87 RS Rating
BridgeBio Pharma stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 64 to 87. 
Via Investor's Business Daily
NASDAQ:EXEL appears to be flying under the radar despite its strong fundamentals.
EXELIXIS INC (NASDAQ:EXEL) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
Expert Outlook: Exelixis Through The Eyes Of 19 Analysts
Via Benzinga
NASDAQ:EXEL is showing decent growth, but is still valued reasonably.
EXELIXIS INC (NASDAQ:EXEL) is showing good growth, while it is not too expensive. 
Via Chartmill
SpringWorks Therapeutics Stock Sees RS Rating Jump To 86
On Monday, SpringWorks Therapeutics stock hit a key technical milestone, seeing its Relative Strength Rating jump to 86. 
Via Investor's Business Daily
Do Not Get Caught Holding Story Stocks- The Market Is Unforgiving
The stock market is already oversold, just not washed out yet. 
Via Talk Markets
Topics Stocks / Equities
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
SpringWorks Therapeutics Stock Gets A RS Rating Lift
The Relative Strength (RS) Rating for SpringWorks Therapeutics stock entered a higher percentile Wednesday, as it got a lift from 62 to 76. 
Via Investor's Business Daily
Arcellx Stock Earns 82 Relative Strength Rating
Arcellx stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82. 
Via Investor's Business Daily
Investors should take notice of NASDAQ:EXEL—it offers a great deal for the fundamentals it presents.
EXELIXIS INC (NASDAQ:EXEL) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Via Benzinga
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends. 
Via Benzinga
2 Biotech Stocks to Buy Hand Over Fist in December
Via The Motley Fool
End Of Year Rally: 3 Stocks To Watch (InterDigital, Futu Holdings, Exelixis)
As the calendar winds down, the stock market often heats up. This 
Via Talk Markets
Topics Stocks / Equities
Ten Young Ones
Here are a variety of lesser-known charts from my “Recents” watch list. Quite a few of them look like good bullish plays. 
Via Talk Markets
Topics Stocks / Equities
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.